EDE visits 2 Korean CGT firms as UAE clinics weigh AED 1.4m-plus therapies

Emirates Drug Establishment (EDE) Director General Dr. Fatima Al Kaabi visited Biosolution and Helixmith in Seoul to discuss cell and gene therapy cooperation, Korea Biomedical Review reported on 9 September 2026.

The visit matters first to CFOs, medical directors and COOs in Dubai clinics and hospitals. Cell and gene therapies can shift a case from routine specialty care to a high-cost, multi-department episode. In Dubai, Dubai Health Authority (DHA) facility licensing and clinical governance sit beside EDE product regulation. In Abu Dhabi, Department of Health Abu Dhabi (DOH) rules apply to providers. In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, Ministry of Health and Prevention (MOHAP) facility oversight remains the relevant local frame.

What EDE is testing with Korea

Korea Biomedical Review said Al Kaabi's visit included Biosolution and Helixmith's R&D centre and a roundtable with Korean companies developing cell and gene therapies (CGTs). EDE is the federal authority for pharmaceuticals, medical devices and health-related technologies. EDE's own site says it was established on 29 September 2023 and regulates medical and pharmaceutical products, including stem cells, blood-derived products and genetically modified organisms.

The two Korean companies give UAE operators different signals. Biosolution is linked to CartiLife, an autologous cartilage-derived chondrocyte therapy for cartilage defects. Public trial records for CartiLife list a 48-week structural and pain-function endpoint in Korea. Helixmith is a gene therapy developer known for Engensis (VM202), a plasmid DNA programme studied in painful diabetic peripheral neuropathy and other vascular or neuromuscular indications.

No UAE approval, pricing decision or distribution contract was announced in the Korea Biomedical Review report. That distinction matters. A regulator visit is a market-access signal, not a treatment launch. For UAE providers, the next checkable events are EDE product registration, a local sponsor or marketing authorisation holder, and any DHA, DOH or MOHAP circular covering administration sites.

The P&L issue is reimbursement

CGT economics are outside the normal pharmacy budget. Older US list prices for commercial CAR-T therapies were about $373,000 to $475,000, equal to roughly AED 1.37 million to AED 1.74 million before hospitalisation, intensive monitoring and management of adverse events. More recent one-time gene therapies have been priced higher. Hemgenix for haemophilia B was priced at $3.5 million, about AED 12.9 million, and Lenmeldy for metachromatic leukodystrophy was priced at $4.25 million, about AED 15.6 million.

Those figures are international reference points. They are not UAE tariffs. UAE finance teams should treat them as a ceiling-risk screen and request four items before contracting: EDE registration status, manufacturer patient eligibility criteria, total episode-of-care estimate, and payer pre-authorisation language. For large payers including Daman, Thiqa and Sukoon, the immediate question is whether the policy wording treats CGT as a covered medicine, a procedure, an experimental therapy, or a special approval case.

• Clinics should confirm whether they can only refer, or whether their licence permits cell handling, infusion and follow-up.
• Hospitals should map pharmacy, laboratory, ICU, infection control and consent workflows before accepting CGT patients.
• Insurers should build a separate review path for single-administration claims above AED 1 million.
• Patients should ask for written eligibility, expected stay, adverse-event monitoring and uncovered costs before travel or deposit payment.

What UAE operators should watch next

Dubai is the first commercial test because private specialty care, medical tourism demand and insurer negotiation are concentrated there. A Dubai provider considering CGT should start with DHA licensing scope and EDE product status, then check whether the therapy requires hospital-level monitoring. Abu Dhabi operators should add DOH quality and claims requirements, especially for Thiqa-linked pathways. Northern emirates providers should verify MOHAP facility permissions before marketing any regenerative medicine service.

The medical risk is as material as the invoice. Many CGTs require strict patient selection, chain-of-identity controls, cold-chain logistics and adverse-event protocols. A marketing campaign that runs ahead of EDE approval or local facility permission creates liability for the medical director and the owner.

The next practical marker is documentary. Operators should watch for an EDE registration entry, a UAE distribution announcement, or a DHA, DOH or MOHAP circular naming CGT service requirements. Until then, clinics should avoid listing Biosolution or Helixmith therapies as available in the UAE. Patients seeking licensed pharmacy providers can check the UAE Open Healthcare Directory before contacting a provider.